Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment

a technology of adenosine receptor and osteoarthritis, applied in the field of treatment, can solve the problems of a large number of joints affected, a higher frequency of hip joint invasion, and a weak muscle strength, so as to prevent the development of osteoarthritis

Inactive Publication Date: 2008-12-04
CAN-FITE BIOPHARMA LTD
View PDF4 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009]Further, the present invention provides a method for the treatment of osteoarthritis in a mammal subject, the method comprises administering to said subject in need of said treatment an amount of an A3AR agonist, the amount being effective to treat or prevent the development of osteoarthritis.

Problems solved by technology

Over time, the cartilage, covering the ends of bones in a joint, begins to break down and may wear away entirely, and the bones will rub together, causing pain.
Due to pain in a joint, the surrounding muscle is used less, and muscle strength is thus weakened.
However, in women a greater number of joints are affected, while men suffer from a higher frequency of hip joint invasion.
Osteoarthritis itself does not greatly affect one's life, but chronic osteoarthritis sustaining for a long period of time causes pain and deformity of the joints and thus reduces the quality of life.
Currently there is no known medical treatment to reverse the effects of this cartilage damage.
However, due to their serious side effects, these drugs are used with special caution.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment
  • Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment
  • Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0146]The effect of IB-MECA (herein at times CF101) alone or in combination with MTX, on the proliferation of the human or rat fibroblast like synoviocytes (FLS) was tested. An effect on proliferation of FLS is suggestive of potential therapeutic effect in osteoarthritis.

Human FLS Cultures

[0147]Human synovial fluid samples were collected from osteoarthritis (OA) patients undergoing paracenthesis. The fluid was centrifuged and the supernatant removed. The cells were resuspended in DMEM containing type I collagenase (4 mg / ml), for 2 hours, and shacked vigorously at 37°. The released cells in the supernatant were harvested by centrifugation and were cultured in DMEM containing 10% FBS, 2 mM glutamine, 100 U / ml penicillin, 100 μg / ml streptomycin, 1% non essential amino acids, 1% sodium pyruvate and 20 mM HEPES buffer in a 37° C., 5% CO2 incubator. After overnight culture, non-adherent cells were removed. The adherent cells (FLS) were subcultured at a 1:2 ratio, and the cells from passag...

example 2

[0152]In the following study the effect of 13-ME CA (herein, at times, CF101) on the development of experimental osteoarthritis (OA) was determined. In this study the monoidoacetate (MIA) experimental model was utilized. The MIA is a rat experimental model that rapidly reproduces the clinical and pathological characteristic of OA. MIA is an inhibitor of glycolysis which has been shown to induce chondrocyte death in vitro. Intraarticular injection of MIA induces chondrocyte death in the articular cartilage of rodent.

[0153]Specifically, male Wistar rats (˜200 gr) (Harlan laboratories) were anesthetized with Isoflurane and the right leg was flexed at a 90° angle of the knee. The MIA was dissolved in physiological saline and 2 mg, at a volume of 50 μL were injected intraarticular of the right foot of each animal, using a 27-gauge, 0.5-inch needle.

[0154]Treatment with CF101, 100 μg / kg, Per Oz (PO), twice daily was initiated at day 7 post-injection.

[0155]Knee diameter was measured using c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
angleaaaaaaaaaa
volumeaaaaaaaaaa
Login to view more

Abstract

The present invention provides the use of an A3 adenosine receptor agonist (A3AR agonist) for the preparation of a pharmaceutical composition for the treatment of a mammal subject having osteoarthritis (OA), as well as to a method for the treatment of OA in a mammal subject, the method comprises administering to said subject in need of said treatment an amount of an A3AR agonist, the amount being effective to treat or prevent the development of OA. Preferred but not exclusive A3AR agonists in accordance with the invention are IB-MECA and Cl—IB-MECA. The A3AR agonist may be administered in combination with another drug, such as, Methotrexate (MTX). The invention also provides pharmaceutical compositions for treatment of osteoarthritis comprising an amount of an A3AR agonist.

Description

FIELD OF THE INVENTION[0001]This invention relates to therapy and in particular to treatment of osteoarthritis.BACKGROUND OF THE INVENTION[0002]Osteoarthritis, known in the past as degenerative arthritis, is the most common form of arthritis. It is a joint disease that occurs after abnormality or damage of joints or without joint damage. The disease involves the deterioration of cartilage in the joints. Over time, the cartilage, covering the ends of bones in a joint, begins to break down and may wear away entirely, and the bones will rub together, causing pain. Due to pain in a joint, the surrounding muscle is used less, and muscle strength is thus weakened.[0003]The usual symptoms of osteoarthritis are stiffness, limitation of motion, pain and joint deformity and affected joints display edema, hot flashes and abnormal enlargement of joints.[0004]The prevalence of osteoarthritis is similar in men and women. However, in women a greater number of joints are affected, while men suffer ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7076A61P19/02
CPCA61K31/00A61K31/519A61K31/7076A61K2300/00A61K31/706A61P19/02A61P29/00A61P43/00A61K9/0053A61K45/06
Inventor FISHMAN, PNINA
Owner CAN-FITE BIOPHARMA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap